Immunocore Holdings (NasdaqGS:IMCR) has drawn attention after recent share price moves, with the stock up around 22% over the past month and roughly 6% in the past 3 months.

The recent 21.55% 1 month share price return suggests momentum in Immunocore Holdings is picking up, although the 1 year total shareholder return is still down 2.31% and the 3 year total shareholder return is down 47.30%. This means recent gains sit against a weaker longer term backdrop.

If this kind of move has you looking beyond a single stock, it could be a good moment to scan other healthcare AI opportunities using the 40 healthcare AI stocks

Bulls point to Immunocore Holdings' revenue growth and pipeline breadth, while bears highlight ongoing losses and past share price declines. Which side does the current valuation lean toward as the stock re-rates?

Most Popular Narrative: 49.3% Undervalued

Against Immunocore Holdings' last close at $33.78, the most followed narrative points to a fair value of $66.57, framing recent price strength as only part of the story.

Momentum in pipeline diversification, progressing late-stage trials in cutaneous melanoma (TEBE-AM, PRISM-MEL) and expanding into infectious and autoimmune diseases, reduces single-product risk and sets the stage for multiple future revenue streams and earnings expansion.

Curious what has to happen for that higher fair value to stack up? The narrative leans on robust revenue growth, margin expansion, and a future earnings profile that looks very different to today.

Result: Fair Value of $66.57 (UNDERVALUED)

However, Immunocore Holdings still leans heavily on KIMMTRAK for revenue and faces rising R&D spend, so any clinical or reimbursement setbacks could quickly challenge this positive setup.

Next Steps

With sentiment around Immunocore Holdings clearly mixed, it makes sense to move quickly and weigh the data for yourself. A good place to start is the 2 key rewards.

Looking for more investment ideas beyond Immunocore Holdings?

If Immunocore Holdings has sparked fresh thinking about your portfolio, do not stop here. Broader, well researched stock lists can help you spot opportunities earlier.

• Target potential value plays by running through the 44 high quality undervalued stocks that combine quality fundamentals with marked-down prices.
• Strengthen your core holdings with the solid balance sheet and fundamentals stocks screener (47 results) focused on companies that pair financial resilience with consistent fundamentals.
• Get ahead of the crowd with the screener containing 19 high quality undiscovered gems that highlights lesser known stocks with stronger fundamentals than their visibility suggests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.